|Articles|February 29, 2012

Dr. Robert Dubois On Promoting Comparative Results Vs. Methodology

Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, discusses the different circumstances in the level of restrictions and evidence regarding comparative effectiveness research. In addition, Dr. Dubois asks whether the standards around safety differ from those around efficacy.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Dr. Robert Dubois On Promoting Comparative Results Vs. Methodology

Related Content

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

OPTIMA Finds Genomic Test Identifies Who Can Skip Breast Cancer Chemo: Iain MacPherson, PhD

Better Data, Community Trust Necessary to Address CVD Disparities in Early-Onset CRC: Meng-Han Tsai, PhD

Rewriting the Rules on Multiple Myeloma Resistance: Ajai Chari, MD

From EASL 2026: What Hepatology Still Needs to Solve

Trending on AJMC

Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata

First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA

5 Notable Oncology FDA Approvals Granted in May

Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story

Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years